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Abstract
Background: Psychotic disorders affect up to 3% of the population and are often chronic and disabling. Innovation
in the pharmacological treatment of psychosis has remained stagnant in recent decades. In order to improve
outcomes for those with psychotic disorders, we present a protocol for the trial of a common food preservative,
sodium benzoate, as an adjunctive treatment in early psychosis.
Methods: Persons experiencing early psychosis (n = 160) will be recruited through hospitals and community mental
health services in Queensland, Australia. Patients will be randomized to receive either 12-week treatment with
1000 mg (500 mg twice daily (BD)) sodium benzoate or placebo. Patients will undergo fortnightly outcome
assessments, in addition to weekly ongoing capacity to consent, drug compliance and safety assessments. The
primary outcome measure is the Positive and Negative Syndrome Scale (PANSS) total score. Secondary outcomes
are Global Assessment of Function (GAF), Assessment of Quality of Life Scale (AQOL), the Activity and Participation
Questionnaire (APQ6), International Physical Activity Questionnaires (IPAQ), Simple Physical Activity Questionnaire
(SIMPAQ), Physical Activity Questionnaire, Clinical Global Impression (CGI), Hamilton Depression rating Scale-17
items (HDRS), Opiate Treatment Index (OTI) and the Patients’ Global Impression of Improvement (PGI-I). As a tertiary
objective, changes from baseline to endpoint in to serum markers related to D-alanine, L-alanine, D-serine, L-serine,
glycine and glutamate will be investigated.
Discussion: Consumers and clinicians are keen to help develop better treatments for those with psychosis. This
study, part of the wider Cadence clinical trials platform will examine if a safe and accessible food preservative can
help optimize outcomes in those with psychosis.
Trial Registration: Australian New Zealand Clinical Trials registry (ANZCTR), ACTRN12615000187549. Registered on
26 February 2015.
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Background
Psychotic disorders are characterized by disturbances to
cognition, affect, perception and behaviour. Approxi-
mately three percent of people in the population are af-
fected by psychosis; onset is commonly in the second or
third decade of life with male individuals at higher risk.
While antipsychotic drugs and supportive therapies re-
duce the symptom burden and rate of relapse to a cer-
tain extent, many will have persistent symptoms and
concomitant cognitive and social disabilities, poor phys-
ical health and curtailed life expectancy [1, 2]. The
pharmacological treatment of psychotic disorders has
seen little innovation in recent decades. No treatment is
documented as efficacious for primary negative symptoms
and cognitive impairments. In addition, current medica-
tions for psychosis are associated with side effects such as
weight gain and metabolic syndrome. Pharmacological
therapy for psychosis yields inconsistent results with a
sizeable proportion of patients only partially responding
to treatment or remaining treatment-resistant [3]. To re-
duce the personal, social and economic burden associated
with psychotic disorders, it is imperative to investigate
novel methods of therapeutic treatment in psychosis.
Novel interventions for psychosis
Traditionally pharmacological treatments of psychotic
illness have predominately focused on modulating the
dopaminergic system. However, recent evidence suggests
that modulation of the glutamatergic system also plays a
vital role as has been shown by abnormalities in gluta-
matergic neurotransmission mediated by N-methyl-D-
aspartate (NMDA) (a subtype of glutamate receptors) in
schizophrenia [4]. NMDA receptors can be simplified
into two main subunits, the glutamate and glycine bind-
ing sites. Options for enhancing NMDA function are
limited to agonists or modulators of the glycine binding
site, as increasing glutamate levels causes excitotoxicity
of neural cells.
The D-amino-acids, D-serine and D-alanine, act as full
agonists of the glycine binding site and have shown
some promise as an adjunct therapy for treatment of
schizophrenia [5]. On meta-analysis [5], the use of D-
serine as an adjunct with antipsychotics was found to
improve total psychopathology (Cohen’s d effect size and
95% confidence intervals) 0.40 (0.07–0.73), negative
symptoms, 0.48 (0.06–0.90) and notably, also to improve
cognitive symptoms 0.42 (0.12–0.73). D-serine also pro-
duced a borderline significant improvement in depres-
sive symptoms 0.39 (−0.01–0.79); however, it had no
effect on positive symptoms or general psychopathology.
D-alanine has only been investigated in one randomized
controlled trial as an adjunct therapy in patients with
schizophrenia and has shown similar promise to that of
D-serine [6].
A limiting factor with the use of D-serine and D-alanine
as adjunct treatments are their oxidization by a flavoen-
zyme, D-amino acid oxidase (DAAO) [7, 8]. This process
both limits the bioavailability of these amino acids, lessen-
ing their effectiveness, and increases products that are po-
tentially nephrotoxic in high doses [9, 10]. This limitation
has led to interest in compounds that may inhibit the ac-
tivity of DAAO, and thus lead to an accumulation of en-
dogenous D-alanine. One inhibitor of DAAO is the widely
used food preservative sodium benzoate. Experimental
animal studies have confirmed that sodium benzoate di-
minishes DAAO’s ability to oxidize D-serine and D-
alanine, resulting in increased cerebral concentration of
these D-amino acids [11].
Rationale for the use of sodium benzoate for the
treatment of schizophrenia
In a recent clinical trial, 52 patients with chronic schizo-
phrenia were assigned to adjunct placebo or adjunct so-
dium benzoate (1000 mg per day) treatment for a period
of 6 weeks [12]. At the end of the study period all do-
mains of the Positive and Negative Syndrome Scale
(PANSS) had improved by an average of 21% (with effect
sizes (ES) of 1.16–1.69) and neurocognitive testing
showed improved processing speed (P = 0.03, ES = 0.65)
and visual learning and memory (P = 0.02, ES = 0.70).
Other domains remained unchanged. There was no in-
crease in adverse effects in the sodium benzoate or the
control group. In the benzoate group there was one re-
corded case of tachycardia, one of weight gain and two
of insomnia. The authors suggested these events were
likely coincidental observations [12].
There is also evidence related to the use of sodium
benzoate in other mental disorders. A randomized,
double-blind, placebo-controlled trial investigating the
use of sodium benzoate in patients with Alzheimer dis-
ease was identified [13]: 60 patients with amnestic mild
cognitive impairment or mild Alzheimer disease were
treated with a variable dose of sodium benzoate (250–
750 mg/day) for a period of 24 weeks. Patients treated
with sodium benzoate performed better in the cognitive
subscale of the Alzheimer’s disease Assessment Scale (P
= 0.0031) than those on placebo, and in the cognition
composite (P = 0.0007) and the clinician interview-based
impression of change plus caregiver input (P = 0.012)
[13]. It was also noted that sodium benzoate was well-
tolerated without any evident side effects.
Sodium benzoate has also been reported in three case
studies. Each patient was administered a 6-week trial of
sodium benzoate (500 mg per day) in patients who had
refused conventional medications. Two of these were
drug-naïve patients with major depression. Over the 6-
week course there was a reduction in the Hamilton Rat-
ing Scale for Depression (Ham-D) score in the first
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patient, which fell from 25 to 9; likewise, in the second
patient with depression, the depression scores dropped
after treatment [14, 15]. Last, a patient experiencing
panic disorder with somatic symptoms had a reduction
in the Panic Disorder Severity Scale from 18 to 7 and an
associated reduction in somatic symptoms [16]. Al-
though these cases are encouraging it is difficult to dif-
ferentiate improvements due to sodium benzoate from a
placebo effect.
In recent decades there has been considerable atten-
tion to optimizing treatments during the first few years
of onset [17, 18]. Often described as “early psychosis”,
this field of research believes that assertive treatments
initiated soon after onset may have better outcomes,
compared to the same treatments when given to individ-
uals with longstanding, chronic psychotic disorders. To
date, we are not aware of studies that have examined the
efficacy of sodium benzoate as a treatment in those with
early psychosis. In our study, we will include patients
within two years of the onset of psychotic disorders.
Safety profile of sodium benzoate
The acute toxicity of oral sodium benzoate in humans is
low. There is evidence that some atopic individuals may
be sensitive to food additives and preservatives (benzoate
is a food preservative). Thus, participants were screened
and excluded when a past history of allergies or intoler-
ance of any food additives was identified (see “Inclusion
and exclusion criteria”).
While the use of sodium benzoate for treatment in
psychiatric disorders in humans is a contemporary pro-
cedure, it has also been used since the late 1970s to treat
patients with urea cycle enzymopathies that cause hyper-
ammonaemia [19–21]. The therapeutic dose adminis-
tered to treat hyperammonaemia over several years is in
the range of 250–500 mg/kg body weight per day, which
equates to 17,500–35,000 mg per day for a body weight
of 70 kg. It is noted that at this dose level, the clinical
signs of toxicity are rare and are limited to anorexia and
vomiting, especially after large intravenous bolus injec-
tions with 100% bioavailability. Recently, Lane et al. [12]
used a dose of 1000 mg of sodium benzoate per day in
their study with no significant differences in side effects
between the treatment and placebo groups.
There is substantial safety information available for so-
dium benzoate because it is used as a common food pre-
servative for products such as salad dressings,
carbonated drinks, jams, fruit juices and other condi-
ments. On labels, the inclusion of sodium benzoate is in-
dicated by the code E211. The US Food and Drug
Agency (FDA) has classified sodium benzoate as “Gener-
ally Recognized As Safe” and regulates the concentration
of sodium benzoate to 0.1% by weight in food products
and 1% concentration in medicines [22, 23]. The current
acceptable daily intake of 0.5 mg/kg body weight is sug-
gested by the joint committee of the Food and Agricul-
ture Organization of the United Nations (FAO) and the
World Health Organization (WHO) [24]. It is noted that
intake estimations from several counties are averaged at
0.18–2.3 mg/kg body weight; however, individuals in
China can consume up to 14 mg/kg body weight per day
from diet alone (i.e. 980 mg per day in a person weigh-
ing 70 kg) [25].
The International Programme on Chemical Safety
(IPCS) published a report on sodium benzoate (and a re-
lated compound, benzoic acid) in 2000 detailing the po-
tential health effects of sodium benzoate in animal
studies. Testing in rodents revealed a low rate of toxicity
with mean lethal dose (LD50) values >1940 mg/kg body
weight. Drawing evidence from two long-term studies
(12–16 months) in rodents, there was no evidence to
suggest sodium benzoate had carcinogenic properties.
Likewise, studies of the precursors of benzoic acid - ben-
zyl acetate, benzyl alcohol, and benzaldehyde - suggest
that sodium benzoate is unlikely to have a carcinogenic
effect. The results of genotoxic activity were inconclusive
in the IPCS report, and there was no consistent abnor-
mal findings based on the Ames test. Based on in vitro
studies of human lymphoblastoid cell lines, the evidence
suggests that sodium benzoate at very high concentra-
tions does have genotoxic effects.
Sodium benzoate does have embryotoxic and fetotoxic
effects; however, these are only evident at a dosage high
enough to cause severe maternal toxicity. A no observ-
able adverse effect level (NOAEL) of approximately
1310 mg/kg body weight for teratogenic effects in ro-
dents was established [26].
Study objectives and hypothesis
The primary objective is to determine if 12-week
treatment with 1000 mg (500 mg twice daily (BD))
sodium benzoate improves the PANSS total score
compared to placebo. The secondary objectives are to
determine if 12-week treatment of 1000 mg (500 mg
BD) sodium benzoate improves scores in the PANSS
subscales, the Global Assessment of Function (GAF),
the Assessment of Quality of Life Scale (AQOL), the
Activity and Participation Questionnaire (APQ-6), the
International Physical Activity Questionnaires (IPAQ),
the Simple Physical Activity Questionnaire (SIMPAQ),
the Clinical Global Impression (CGI), the Hamilton
Depression rating Scale-17 items (HDRS), the Opiate
Treatment Index (OTI) and the Patients’ Global Im-
pression of Improvement (PGI-I), compared to pla-
cebo. As a tertiary objective, changes to sera markers
related to D-alanine, L-alanine, D-serine, L-serine,
glycine and glutamate change from baseline to end-
point will be investigated.
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It is hypothesised that 1) participants allocated to the
active arm (1000 mg (500 mg BD)) Sodium Benzoate
treatment will have significant reductions in PANSS total
score at week 12 compared to individuals taking placebo;
2) sodium benzoate treatment will improve scores on
secondary scales relative to placebo; and 3) for patients
who have received stable primary medication during the
trial, only those allocated to the active arm will have
modified levels of sera markers related to D-alanine, L-
alanine, D-serine, L-serine, glycine and glutamate.
Study design
The design is a randomized, placebo-controlled, double-
blind parallel-group trial to examine the clinical efficacy and
safety of add-on treatment with sodium benzoate for persist-
ent symptoms in patients with early psychosis. Standard
Protocol Items: Recommendations for Interventional Trials
(SPIRIT) guidelines and checklists were followed for this
protocol [27, 28] (Additional file 1: Table S1).
In this study 160 individuals with early psychosis will be
recruited. Participants will be given either 1 g/d (500 mg
BD) of sodium benzoate or placebo (microcrystalline cel-
lulose in matched gelatine capsules), in addition to their
normal routine care. Routine care is defined as “individu-
alized combinations of psychopharmacology, behavioural
interventions, rehabilitation and associated clinical ser-
vices” in keeping with Queensland Health standards of
care. Face-to-face clinical assessments will be at baseline
(week 0) and weeks 2, 4, 6, 8, 10 and 12. Weekly phone
contact (if no phone then face-to-face assessment) will
occur in between face-to-face visits. A post-completion
visit will be conducted at week 14. Participants will be
contacted regularly by weekly telephone calls to monitor
adherence and compliance.
Allocation sequence and concealment
Randomization will be carried out using a computer-
generated randomization table, stratified by five sites.
Each of the five sites will have separate randomization
tables, and each list will ensure randomization is blocked
in groups of four. Participants will receive either active
treatment or placebo in a 1:1 ratio. The allocation se-
quence will be generated by an independent statistician,
and the distribution of the study medication will be su-
pervised by an independent research pharmacist.
Study population
One hundred and sixty participants will be recruited
through hospitals and community mental health services
in Queensland, Australia.
Inclusion and exclusion criteria
The inclusion criteria include: (1) onset of a psychotic
disorder within the last 2 years; (2) diagnosis of
psychotic disorders according to the Diagnostic and
Statistical Manual of Mental Disorders, 4th. Edition
(DSM-IV), which include schizophrenia, schizophreni-
form psychosis, delusional disorder, bipolar disorder and
psychosis not otherwise specified; (3) age between 15
and 45 years; 4) treatment with antipsychotic medica-
tions for a period of at least one continuous month
within the 2-year period as in “(1)”; (5) PANSS total
score of at least 55 (i.e. those who have at least moderate
symptoms) [29, 30] and (6) agreement to participate,
and capacity to consent and be able to follow the study
instructions and procedures.
The exclusion criteria include: (1) known allergies to
sodium benzoate (E211) or any part of the formulation
of the investigational product; (2) suspected allergies or
known adverse reactions to food preservatives in gen-
eral; (3) comorbid physical illnesses that would impair
the participant’s ability to complete the trial (e.g. a gen-
eral medical disorder requiring additional treatments
and/or hospitalization); (4) inability to understand or
communicate in English; (5) currently pregnant, plan-
ning to become pregnant or lactating during the study
period and (6) inability to follow the study instructions
and procedures.
Sample size determination
The study by Lane et al. was based on 52 patients with
chronic schizophrenia [12]. They reported a Cohen’s ef-
fect size (d) of 1.53. Our patients (with early psychosis)
tend to have slightly lower mean PANSS total scores
(65.0), with a standard deviation of 14.3 units and it is
anticipated that the effect size will be smaller in this
group. With an alpha value of 0.05, and power of 0.8, we
wish to be able to confidently detect a difference in
mean PANSS total score of at least 7 units. This will re-
quire 66 participants per group (n = 132). Over a 12-
week period we predict an attrition rate of 15%. Thus,
we will need to randomize approximately 160 subjects.
Randomization and blinding procedure
Participants will be randomized to one of the treatment
groups, using blocks of four via a computer-generated
randomization table. Randomization will be stratified by
five sites: (a) Metro North Hospital and Health Services
(HHS), (b) Metro South HHS, (c) West Moreton HHS,
(d) Gold Coast HHS and (e) Children’s Health Queens-
land HHS. Participants will be allocated to receive either
active treatment or placebo in a 1:1 ratio.
The investigational products will be manufactured in ac-
cordance with current Good Manufacturing Practice
(GMP) in a suitable Therapeutic Goods Administration
(TGA) licensed facility. This same company (Pharmaceut-
ical Packing Professionals) will hold the randomization
code. Participants will be randomized strictly using a
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chronological process. Participants will be allocated a unique
identification number, which will be linked to the specific
site number. The randomization will be double-blind. An in-
dependent biostatistician will generate the randomization
list, which will be provided to the manufacturer.
Unblinding
The independent manufacturer will hold the closed
randomization list and only the manufacturer will have
the ability to unblind the allocation. In the case of an
emergency when it is crucial the medical staff knows
whether the participant is on sodium benzoate or pla-
cebo, participants will be provided with contact informa-
tion (i.e. 24-hour telephone number) for unblinding the
allocation. After study completion by all participants
(last patient last visit), the participants will be notified as
to which arm of the study they took part in.
Drug administration
The “intervention” group will receive 1000 mg sodium
benzoate (500 mg BD with meals-reminder aid) in the
form of capsules and the “placebo group” will receive
microcrystalline cellulose gelatine capsules with an iden-
tical appearance. Sodium benzoate will be dispensed to
participants once consent has been obtained and after
the screening phase and randomization. A delegated Re-
search Pharmacist will dispense medication for all sites.
The entire 12 weeks of study medication for each ran-
domized participant will be provided to QCMHR dele-
gated research staff. The study medication will then be
distributed to the participant on a fortnightly basis by
delegated research staff. There will be a total of seven
dispensations per participant.
Dose justification
The FAO/WHO Expert Committee on Food Additives
established a preliminary acceptable daily intake of up to
5 mg/kg body weight for sodium benzoate as a food pre-
servative [24]. This translates to 350 mg per day for a 70-
kg person. With respect to individuals with urea cycle dis-
orders, the recommended dose of sodium benzoate is be-
tween 250 and 500 mg/kg per day or approximately
17500 mg–35000 mg per day for a 70-kg person. It is
noted that serious side effects at this dosage are rare and
limited to occasional cases of anorexia and vomiting [31].
In the use of sodium benzoate for the treatment of
schizophrenia, we are guided by the dose used by Lane
and colleagues [12]. In the main study the investigators
also described a pilot study (n = 7) dosing sodium benzo-
ate between 250 and 1000 mg/d: in this study, 1000 mg/
day resulted in the largest decrease in psychotic symp-
tomatology, with no evident adverse reactions. In this
patient group, a dose of 1000 mg per day was not associ-
ated with significantly more adverse events (AEs)
compared to placebo. Treatment-emergent AEs included
weight gain (n = 1), insomnia (n = 2), and tachycardia (n
= 1). It was noted that these AEs were mild, brief and
did not warrant medical treatment. The authors con-
cluded these events were likely coincidental observa-
tions. Routine blood cell count, chemical analysis results
and electrocardiogram after treatment remained un-
changed and were all within normal ranges [12].
Comparator justification
This study will use a placebo adjunct to routine care as
a comparator condition. Routine care in this study is de-
fined as “individualized combinations of psychopharma-
cology, behavioural interventions, rehabilitation and
associated clinical services” in keeping with Queensland
Health standards of care for psychosis. The Declaration
of Helsinki affirms that placebo-controlled trials should
only be used in the absence of existing proven therapy
[32]. Therefore, the use of an adjunct therapy has been
selected to ameliorate these ethical concerns as both the
experimental and control groups will receive standard
medical care (treatment as usual).
Outcome measures
A battery of validated clinical measures, physical health
measures (blood pressure, waist circumference, height,
weight and body mass index (BMI)) and AEs will be col-
lected at baseline and at weeks 2, 4, 6, 8, 10 and 12.
Efficacy measures
The PANSS total score, a widely used scale for measur-
ing symptom severity in patients with schizophrenia, will
be used as the primary outcome measure.
Secondary outcome measures will include the follow-
ing clinical assessments:
 The PANSS subscales, including Positive, Negative
and General Psychopathology subscales
 The GAF, which is a numeric scale (1–100) used by
mental health clinicians and physicians to
subjectively rate the social, occupational, and
psychological functioning of adults
 The CGI, which is used to measure symptom
severity, treatment response and the efficacy of
treatments in treatment studies of patients with
schizophrenia
 The Hamilton Depression Rating Scale-17items
(HDRS), which is a multiple-item questionnaire used
to provide an indication of depression and a guide to
evaluate recovery
 The AQOL, which is a 15-item instrument that
measures five broad domains: psychological well-
being, physical senses, social relationships, independ-
ent living and illness
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 The OTI, which is a comprehensive evaluation tool
that assesses participants’ drug and alcohol use over
the previous month: drugs assessed include heroin,
other opiates, alcohol, cannabis, amphetamines,
cocaine, tranquillizers, barbiturates, hallucinogens,
inhalants, tobacco and poly-drug use
 The APQ-6, which is a short 6-item measure de-
signed to complement clinical assessment, to sup-
port dialogue between consumers and clinicians
about recovery goals, and to allow monitoring of
change over time at both individual and aggregated
service levels [23]
 The IPAQ, which provides a common instrument
that can be used to obtain internationally
comparable data on health-related physical activity
 The SIMPAQ, which measures physical activity: it
has been designed for use in various populations
including clinical samples with high levels of
sedentary behaviour
 The PAQ, which has been developed to assess
attitudes: it specifically assesses general opinion on
physical exercise, motivators and barriers to exercise
 The PGI-I, which is a self-report scale, whereby a
patient rates their overall improvement as a result of
a therapy
Biomarkers
A 25-ml sample of whole blood will be collected via
venipuncture at both baseline and final patient inter-
views. A portion of this sample will be used to assess the
concentration of key analytes in the pathways related to
sodium benzoate. D-amino acid oxidase is needed to ca-
tabolize D-alanine. D-alanine can be measured in serum
with high-performance liquid chromatography (HPLC)
[33]. Related species that could be altered by the inter-
vention include L-alanine, D-serine and L-serine, glycine
and glutamate. Collecting these measures will allow us
to assess if sodium benzoate impacts on these analytes
in the peripheral blood. The remainder of the blood
sample will be stored indefinitely for future research.
However, future studies involving the stored blood sam-
ples will require approval from a Human Research Ethics
Committee (HREC). In the event that a person objects
to any biological samples being collected and stored,
they will not be excluded from participating in the trial.
Frequency of visits and follow up
Participants will be clinically assessed at baseline and
weeks 2, 4, 6, 8, 10 and 12. The study team will also con-
tact participants once a week in between one-to-one as-
sessments by telephone (if no telephone then by face-to-
face review). Detailed schedule of visits and assessments
are presented in Fig. 1. This protocol was written follow-
ing the SPIRIT checklist.
Compliance monitoring and adherence
Participants will be requested to return all unused study
medication (i.e. unopened blister packs or capsules not
taken) and empty blister packs to the delegated research
assistants. All unused supplies of study medication will
be accounted for and documented by the designated Re-
search Pharmacist. Compliance with study medication
will be calculated at each visit by means of self-report
and a capsule count. These data will be used to calculate
compliance with medication for analysis purposes.
For adherence and compliance monitoring, partici-
pants will be contacted regularly by weekly telephone
calls. To further aid compliance and as a quick visual
guide, participants will be offered a diary to document
the date and time of scheduled visits and tasks to be
undertaken.
A current investigational product dispensing log will
be kept and will contain the following information:
 the identification of the participant to whom the
drug was dispensed
 the date(s) and quantity of the drug dispensed to the
participant
The inventory will be available for inspection by study
monitors during the study. Drug supplies, including par-
ticipant returns, will be collected at the end of the study
by the study monitors, while unused drug supplies may
be destroyed by the Investigator or delegate, provided
such disposition does not expose humans to risks from
the drug. Records will be maintained by the Investigator
of any such alternate disposition of the investigational
product. These records will show the identification and
quantity of each unit disposed of, the method of destruc-
tion (taking into account the requirements of local law),
and the person who disposed of the investigational prod-
uct. Where investigational product is destroyed on site, a
record of destruction will be issued. Such records will be
submitted to the Sponsor for reconciliation purposes.
Case report form
A case report form (CRF) will be completed for each study
participant, summarising all clinical screening and study
data that are to be provided to the University of Queens-
land (Sponsor) for data analysis. In the CRF, participants
will only be identified by their participant number in order
to retain participant confidentiality. The completed CRFs
will be retained by the Investigators for a period of at least
15 years or the maximum time frame as determined by
local regulations, whichever is the longest.
Study restrictions
There are no restrictions to participants during the study
in terms of concomitant medications, exercise or
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ambulation. While sodium benzoate is often added to
products rich in vitamin C such as orange juice, there
has been concern that sodium benzoate may interact
with high-dose vitamin C formulations to produce ben-
zene (a known carcinogen) [34]. There is an absence of
clear guidance on this matter, thus for the purposes of
this protocol, we will adopt a conservative stance and re-
quire patients to avoid using vitamin C formulations that
contain more than 500 mg/day (multivitamin tablets
have lower doses of vitamin C and can be continued
during the study, as can citrus fruits and food products
that contain vitamin C naturally).
Safety assessments
All patients recruited into this study will be current pa-
tients of Queensland Hospital and Health services. The
study team will liaise with clinical staff to ensure that
participants have undergone a routine physical health
screen. Female participants will have a urinary preg-
nancy screen at baseline prior to inclusion, and during
the study if indicated.
Adverse events
The Investigator and designated study personnel will
monitor each participant for AEs during the study. All
AEs reported between consent and final follow-up visit
will be recorded in the CRF. The investigator or desig-
nee will ask the participant non-leading questions in an
effort to detect AEs e.g. “Have you felt unwell or differ-
ent in any way since your last visit”. In addition, partici-
pants will be encouraged to spontaneously report any
unusual feelings or sensations.
Adverse events and serious adverse events
The investigator will be responsible for the detection
and documentation of events meeting the criteria and
definition of an AE or a serious adverse event (SAE). We
have developed a separate database on AE reporting. We
are using the Medical Dictionary for Regulatory Activ-
ities (MEDRA) coding system that includes System
Organ Class (SOC), and following disease symptoms
(lowest level term (LLT)) into the database for detailed
record keeping of all related (and unrelated) AEs/SAEs.
Each AE will be monitored until resolution or to the end
of the 12-week protocol.
Participant withdrawal by the Investigator
Patients will be withdrawn from the study by the Investi-
gator, prior to completion of treatment, under the fol-
lowing conditions:
 Non-compliant with study medication for 7
consecutive days
 Development of an SAE assumed to be associated
with the study medication
 Cessation of effective contraception or confirmed
pregnancy
 Continual inability to provide informed consent
Early termination and stopping rules
The study may be terminated prematurely by the Coord-
inating and or Principal Investigator or his/her designee
and the Sponsor if: (a) the number and/or severity of
AEs justify discontinuation of the study, (b) new data be-
come available, which raise concern about the safety of
the study drug, so that continuation might cause
Fig. 1 Schedule of visits and assessments. GAF Global Assessment of Functioning, AQOL Assessment of Quality of Life, APQ Activity and
Participation Questionnaire, CGI Clinical Global Impression, HDRS Hamilton Depression Rating Scale, OTI Opiate Treatment Index, PGI-I Patients’
Global Impression of Improvement
Ryan et al. Trials  (2017) 18:165 Page 7 of 11
unacceptable risks to participants. Study closure advice
will also be sent to the Reviewing Ethics Committee and
relevant Governance Offices, and the TGA. The Austra-
lian Clinical Trial Registry entry will also be updated ac-
cordingly. Interim analysis may be performed if needed
as aforementioned, and will be conducted by the Univer-
sity of Queensland (Sponsor) data analysis team.
Participant reimbursement and compensation
Participants will be reimbursed for out-of-pocket ex-
penses, inconvenience and time involved, by the
provision of prepaid gift cards from a large retail outlet.
We will provide a gift card worth Australian $40, at the
end of week 2, mid-way through the protocol (week 6)
and on completion (week 12) (total reimbursement Aus-
tralian $120).
The clinical trial insurance will reimburse participants
for costs of medical care that occur as a result of com-
plications directly related to participation in this study.
The Investigator and insurance company will be notified
as soon as possible if this occurs or where a causal rela-
tionship cannot be excluded. All SAEs will be reported
to the nominated insurance company. The University of
Queensland (Sponsor) will enter into a Clinical Trial
Agreement with each of the five Hospital and Health
Services (HHSs) involved in the study, based on the
standard Medicines Australia format
Data management and monitoring
A screening log will be utilized to track potential partici-
pants and also record the counts of individuals
approached, consented, meeting inclusion/exclusion cri-
teria, withdrawn and completed (in keeping with stand-
ard requirements of the Consolidated Standards of
Reporting Trials (CONSORT) diagram). The CRF will
comprise the hard copy questionnaires, clinical assess-
ments and measures. These de-identified data will be
retained in a secure room, in a locked filing cabinet at
each site. De-identified data from the CRFs will be en-
tered into REDCap, which is a secure web-based applica-
tion (encrypted to health-service standard, housed on a
server behind the University of Queensland firewall) for
building and managing online surveys and databases.
Delegated research assistants will be trained in, and be
responsible for, entering data into the database. Upon
completion and resolution of monitoring and data man-
agement queries, the clinical trial database will be
closed. All data will be exported into SAS software to
enable statistical analysis. A copy of the database will be
stored in a secure room in a locked filing cabinet separ-
ate from the CRFs.
The study coordinator or designated delegate will
monitor data entered at each site and be responsible for
resolving data entry errors and discrepancies. Data
quality will be ensured by performing data entry checks
for consistency between the CRF and the data entry into
REDCap database. These checks will be performed dur-
ing data entry so that discrepancies can be resolved im-
mediately. A data manager will later perform additional
checks for completeness and plausibility of data. Result-
ant queries will be raised and resolved electronically by
the data manager and the study centre.
Statistical analysis
All data will be analysed using SAS 9.4. The data will be
provided to the biostatistician(s) employed by the Queens-
land Centre for Mental Health Research for analysis. We
will identify demographic and clinical differences between
the groups at baseline (chi-square test, Fisher exact test
for nominal variables and Mann-Whitney test or inde-
pendent sample t test for continuous variables). Efficacy
will be assessed according to standard intention to treat
(ITT) analytic procedures (i.e. for those who do not
complete the 12-week study period, we will carry forward
their last observation on the study outcomes). Mean
changes in clinical assessment will be assessed using
mixed-model repeated-measure (MMRM) methods with
treatment, week and treatment-week interaction as fixed
effects and intercept as the only random effect; the base-
line value will be the covariant. The MMRM analyses will
be performed using the SAS PROC mixed procedure. P
values will be based on two-tailed tests with significance
levels of 0.05.
Monitoring and quality assurance
An independent Study Monitor will conduct study docu-
mentation review to monitor key features of the study
prior to commencement and during and after study
completion. These site visits will enable the Monitor to
maintain current, personal knowledge of the study
through review of the CRFs, to compare CRF entries
against the electronic database (REDCap) and to discuss
the conduct of the study with the Investigator. The
Monitor will be responsible for monitoring adherence to
the approved study protocol, regulatory compliance in-
cluding GCP and completion of the CRF.
Data Safety Monitoring Board
An independent Data Safety Monitoring Board (DSMB)
will be established specifically to monitor safety data and
study trends throughout the duration of the trial to de-
termine if continuation of the trial is appropriate scien-
tifically and ethically.
Protocol amendments
Any amendments to the protocol will be submitted to
the appointed HREC by the Chief Investigator for ap-
proval. Any approved amendments by the appointed
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HREC will be forwarded by the Chief Investigator for
submission to each Research Governance Office. If a
protocol amendment requires changes to the informed
consent form, the revised informed consent form, pre-
pared by the Chief Investigator, will be approved by the
reviewing ethics committee and site governance officers.
While the amendment affects the ongoing suitability of
the study at a participating site, the Research Govern-
ance Office will determine the ongoing suitability based
on the amendment submitted. The present version is
1.2, 31 October 2015.
Discussion
The Cadence BZ study is the first clinical trial estab-
lished as part of the wider Cadence Clinical Trials
platform [35]. This project, funded by the National
Health and Medical Research Council (NHMRC),
aims to build capacity in clinician trials. To this end,
a multidisciplinary working party was established in
2014, to guide the direction of future clinical re-
search. Treatments that were safe and acceptable to
consumers and caregivers were prioritized - thus in-
terventions were chosen that involve compounds such
as food preservatives (e.g. sodium benzoate) and that
involved augmentation of standard treatments. A web-
site has been developed to provide information to
participants and their families, and for clinicians
(www.cadencetrials.com).
Sodium benzoate appears a promising compound
from several perspectives. It impacts on neurotrans-
mitter pathways of interest to schizophrenia. For ex-
ample, recent large genome-wide association studies
have identified common variants in genes related to the
N-methyl-D-aspartate (NMDA) neurotransmitter system
(https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC4112379/ and https://www.ncbi.nlm.nih.gov/pmc/ar-
ticles/PMC4361495/). The preliminary data from clinical
trials looks promising. It involves a compound that has an
attractive safety profile, and one that is acceptable to par-
ticipants. We have based the dose of sodium benzoate
(1000 mg/day) on the most recent clinical trial [12]. How-
ever, it is feasible that alternative doses may be optimal.
Our study will not be able to explore this issue.
Trial status
The study is currently recruiting participants. Recruit-
ment commenced on 14 August 2015. Currently 50 par-
ticipants have been randomized.
Additional files
Additional file 1: Table S1. SPIRIT 2013 checklist. (DOC 126 kb)
Additional file 2: Table S2. Model consent from (adult). (DOCX 139 kb)
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